New CDC Opioid Guidelines Incite Backlash from Patient Groups
The Centers for Disease Control and Prevention has drafted new guidelines on prescribing opioids for chronic pain—and they could be bad news for patients living with pain.
Will New Value Assessments Lead to Care Rationing?
For patients, the immense value of a life-changing medication can be difficult to quantify.
U.S. Senators Press FDA Director on Unresolved Biosimilar Policy Issues
The Senate Subcommittee on Primary Health and Retirement Security’s September 17 hearing featuring FDA Director Janet Woodcock, MD, resulted in a packed hearing room—and hopes that FDA guidance on unresolved policy issues affecting biosimilars will materialize sooner rather than later.
Cancer Awareness Months Highlight Progress, Challenges
This month advocates, patients and their families reflect on the toll cancer takes, the progress that new treatment options offer and the obstacles that too many patients still face.
New Study: 1 in 4 Patients Initially Denied Hepatitis C Cures
Hepatitis C patients have a one in four chance of receiving curative treatment on their initial request, a new Yale University School of Medicine study reveals.
Biosimilar Cost Savings Disappoint
Biosimilar cost savings have arrived. But they are proving much less robust than proponents had hoped.
IfPA Releases Policy Update on Biosimilars
Five years after the federal government approved an abbreviated regulatory pathway for biosimilars, physicians and patients still lack clarity on a number of core issues.
New AfPA Video Explores Access to Abuse-deterrent Pain Medications
Innovative pill formulations offer a new option for battling prescription opioid abuse, explains a recently released video from the Alliance for Patient Access.
New Study: Parents’ Clothing Could Infect NICU Infants with RSV
Fragile preemies and newborns may face the risk of respiratory syncytial virus (RSV) from the most well-meaning source—their parents.
Australian Regulators Recommend Biosimilar Substitution without Notification
Australian pharmacists could soon substitute a biosimilar infliximab for its reference product without prescribing physicians’ –or even patients’—knowledge.
